Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 9,400 shares at $0.99 ($9K) on 2015-12-04, disclosed to the SEC on 2015-12-04.
Scheduled sale ($9k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.99 | 1,100 | $1K | 11.6% |
| 2 | $0.99 | 200 | $198 | 2.1% |
| 3 | $0.99 | 600 | $594 | 6.3% |
| 4 | $0.99 | 1,500 | $1K | 15.9% |
| 5 | $1.00 | 4,500 | $5K | 48.0% |
| 6 | $1.00 | 200 |
| $200 |
| 2.1% |
| 7 | $1.00 | 300 | $300 | 3.2% |
| 8 | $1.00 | 600 | $600 | 6.4% |
| 9 | $1.00 | 100 | $100 | 1.1% |
| 10 | $1.01 | 100 | $101 | 1.1% |
| 11 | $1.01 | 200 | $202 | 2.2% |
| Total | $1.00 avg | 9,400 | $9K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |
| CTIC | SELL | 2015-10-07 | $15K | — | Filing → |